(Total Views: 562)
Posted On: 03/07/2021 4:48:31 AM
Post# of 155779
Quote:
All that being said, the results show fantastic promise for >65 year olds, critical and on machine assistance.
The 65+ skew in patients was for both severe and critical, corrected for age, good results.
Quote:
Therefore, an “age adjustment” analysis was performed and consequently, the updated results from the primary endpoint analysis are as follows:
1) Statistically significant results (p-value = 0.0319) reported for the primary endpoint (all-cause mortality at Day 28) in participants receiving leronlimab + “commonly used COVID-19 treatments” compared to participants who received “commonly used COVID-19 treatments” alone in the placebo group in the overall modified intent-to-treat (“mITT”) population.
(4)
(0)
